Scientific deep-dive

Is Wegovy the Same as Ozempic? Is Zepbound the Same as Mounjaro? Complete GLP-1 Disambiguation FAQ (2026)

21 patient-language disambiguation questions answered: Is Wegovy the same as Ozempic? (Same active ingredient — semaglutide — different brand, different dose, different indication.) Is Zepbound the same as Mounjaro? (Same molecule — tirzepatide — different brand for different indication.) Is Mounjaro a semaglutide? (No — tirzepatide.) Is Wegovy a GLP-1? (Yes.) Is GLP-1 the same as Ozempic? (No — GLP-1 is a drug class, Ozempic is one specific drug in that class.) The canonical reference for every same-as / vs / class-membership question patients actually search.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
13 min read·7 citations

Frequently Asked Questions

Yes — same active ingredient (semaglutide) made by the same manufacturer (Novo Nordisk), but different brand names for different FDA-approved indications. Wegovy is approved for chronic weight management at a maximum dose of 2.4 mg once weekly. Ozempic is approved for type 2 diabetes at a maximum dose of 2.0 mg once weekly. The pen formats and labeled doses differ.
Yes — same active ingredient (tirzepatide) made by the same manufacturer (Eli Lilly), but different brand names for different FDA-approved indications. Zepbound is approved for chronic weight management and obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes only. The maximum dose (15 mg once weekly) is the same.
Yes — same active ingredient (liraglutide) made by the same manufacturer (Novo Nordisk), but different brands at different maximum doses for different indications. Saxenda is 3 mg/day for chronic weight management. Victoza is up to 1.8 mg/day for type 2 diabetes. Both are once-daily subcutaneous injections.
Same active ingredient (semaglutide), different formulation. Rybelsus is an oral tablet that uses a SNAC absorption enhancer to allow oral delivery of the semaglutide peptide. Ozempic is a subcutaneous injection. Both are FDA-approved for type 2 diabetes only — neither is approved for weight management. Both are made by Novo Nordisk.
No. Mounjaro is tirzepatide, made by Eli Lilly. Tirzepatide is a dual GIP/GLP-1 receptor agonist — chemically and mechanistically distinct from semaglutide. Patients sometimes confuse the two because both are once-weekly injectable peptides for type 2 diabetes, but they are different drugs.
No. Zepbound is tirzepatide, made by Eli Lilly. It is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 receptor agonist like semaglutide. Wegovy is the semaglutide-based product approved for weight management; Zepbound is the tirzepatide-based product approved for weight management. The two are different molecules.
No. Wegovy is semaglutide 2.4 mg, made by Novo Nordisk. It is a pure GLP-1 receptor agonist. Tirzepatide is the active ingredient in Mounjaro and Zepbound, made by Eli Lilly. The two molecules belong to overlapping but distinct classes — semaglutide is GLP-1 only, tirzepatide is dual GIP/GLP-1.
No. Foundayo is orforglipron — an oral non-peptide small-molecule GLP-1 receptor agonist made by Eli Lilly, FDA-approved on April 1, 2026 for chronic weight management. Rybelsus is oral semaglutide — a peptide formulated with a SNAC absorption enhancer, made by Novo Nordisk, FDA-approved for type 2 diabetes only. Different molecules, different chemistry, different indications.
No. Trulicity is dulaglutide — a long-acting GLP-1 receptor agonist Fc-fusion biologic made by Eli Lilly. Ozempic is semaglutide — a synthetic peptide made by Novo Nordisk. Both are once-weekly subcutaneous injections approved for type 2 diabetes, but they are structurally different molecules from different manufacturers.
Yes. Wegovy contains semaglutide, a GLP-1 receptor agonist. The Wegovy DailyMed label describes semaglutide as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is one of the prototypical drugs in the GLP-1 class.
Partially. Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist. The DailyMed label describes it as both a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is often grouped with GLP-1 receptor agonists in clinical conversation, but technically it is a dual-incretin agonist — a different class.
Yes. Foundayo contains orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. It binds to and activates the GLP-1 receptor through an allosteric mechanism distinct from peptide GLP-1 agonists like semaglutide and liraglutide, but it is in the GLP-1 receptor agonist class.
Yes. Trulicity contains dulaglutide, a GLP-1 receptor agonist. The DailyMed label describes dulaglutide as a long-acting GLP-1 receptor agonist consisting of two GLP-1 analog peptides covalently linked to an Fc fragment of human IgG4. It is a biologic GLP-1 receptor agonist.
No. GLP-1 (or GLP-1 receptor agonist) is the name of a drug class — a category of medications that activate the glucagon-like peptide-1 receptor. Ozempic is one specific drug in that class (semaglutide, made by Novo Nordisk, approved for type 2 diabetes). Wegovy, Saxenda, Victoza, Rybelsus, Trulicity, and Foundayo are also GLP-1 receptor agonists, and Mounjaro and Zepbound contain a dual GIP/GLP-1 receptor agonist.
Yes. Semaglutide is a synthetic peptide GLP-1 receptor agonist. It is the active ingredient in Wegovy (weight management), Ozempic (type 2 diabetes), and Rybelsus (oral, type 2 diabetes) — all made by Novo Nordisk.
No. GLP-1 is the broader drug class — every GLP-1 receptor agonist activates the GLP-1 receptor. Semaglutide is one specific molecule within that class. Liraglutide, dulaglutide, exenatide, orforglipron, and (with the dual-mechanism caveat) tirzepatide are also in or adjacent to the GLP-1 class.
No. Wegovy is semaglutide 2.4 mg once weekly. Saxenda is liraglutide 3 mg once daily. Both are FDA-approved for chronic weight management and both are made by Novo Nordisk, but the active ingredients, dosing frequency, and effect sizes differ — semaglutide is the longer-acting and more potent of the two.
No. Wegovy is semaglutide 2.4 mg (Novo Nordisk), FDA-approved for chronic weight management. Mounjaro is tirzepatide up to 15 mg (Eli Lilly), FDA-approved for type 2 diabetes only. Different molecules, different mechanisms (GLP-1 only vs dual GIP/GLP-1), different manufacturers, different indications.
No. Both are FDA-approved for chronic weight management, but they are different molecules. Zepbound is tirzepatide (Eli Lilly, dual GIP/GLP-1 receptor agonist). Wegovy is semaglutide (Novo Nordisk, GLP-1 receptor agonist). The SURMOUNT-5 head-to-head trial published in NEJM in 2025 (PMID 40353578) compared the two directly in chronic weight management.
No FDA-approved generic semaglutide is on the market in the United States as of August 2026. Ozempic and Wegovy remain branded products under Novo Nordisk's patent. Apotex Inc. received tentative FDA approval (ANDA 220314) for generic injectable semaglutide in April 2026, but 'tentative approval' means the generic cannot yet be marketed — it is blocked pending expiration of Novo Nordisk's patent/exclusivity protection. Compounded semaglutide produced by 503A and 503B compounding pharmacies is NOT an FDA-approved generic — it is a pharmacy-compounded preparation, regulated differently from FDA-approved generics. Patients should not refer to compounded semaglutide as a generic.
Yes — FDA-approved generic liraglutide exists and is bioequivalent to the branded reference product. Hikma received FDA approval in December 2024 for the first generic liraglutide referencing Victoza (type 2 diabetes). Teva received FDA approval on August 27, 2025 for the first generic liraglutide 3 mg referencing Saxenda (chronic weight management) — the first generic GLP-1 RA approved for weight management in the United States.
Neither is inherently 'better' — they are the same molecule (semaglutide, Novo Nordisk), so the right choice depends on what is being treated. For chronic weight management, Wegovy is the correct product because it is the FDA-approved weight indication and titrates to a higher maximum dose (2.4 mg once weekly); for type 2 diabetes, Ozempic is the labeled product (up to 2.0 mg once weekly). If weight loss is the goal, the more meaningful comparison is not Wegovy vs Ozempic but Wegovy vs Zepbound (tirzepatide), the two weight-management brands.
The most common downsides are gastrointestinal side effects (nausea, vomiting, diarrhea, constipation), especially during dose titration, plus high cost and inconsistent insurance coverage for the weight-management indication. There is also a boxed warning for thyroid C-cell tumor risk — contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Importantly, weight regain is common if the medication is stopped, because Wegovy manages obesity as a chronic condition rather than curing it. These are educational points, not medical advice; discuss risks with a prescriber.
Both brands contain the same semaglutide molecule, so any price gap reflects indication, dose, and insurance coverage — not a different or 'stronger' drug. Ozempic is frequently covered by insurance for type 2 diabetes, which lowers the out-of-pocket cost, whereas Wegovy's weight-management indication is excluded from many plans, leaving patients exposed to more of the list price. The difference most patients experience is therefore a coverage difference rather than a manufacturing one.

This disambiguation FAQ is part of Weight Loss Rankings' living editorial database — 1,060+ research articles and 570+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels (DailyMed) and peer-reviewed PubMed literature.

The questions patients actually ask Google are not always intuitive. GLP-1 is a drug class — not a specific drug. Wegovy and Ozempic share an active ingredient (semaglutide) but are different brands at different maximum doses for different FDA-approved indications. Zepbound and Mounjaro are the same molecule (tirzepatide) — but tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1, per the verbatim §12.1 mechanism-of-action language in the FDA-approved DailyMed labels [4, 5]. Wegovy and Mounjaro are different molecules entirely. This article works through 21 of the most- searched same-as / vs / class-membership questions with verbatim YES/NO answers anchored to DailyMed [1, 2, 3, 4, 5, 6, 7].

About this article

Source rigor: Every brand → active ingredient → manufacturer → indication mapping in this article was verified against the DailyMed (NIH) FDA label for that product. Brand-vs-generic statements are anchored to the FDA Orange Book and primary FDA approval announcements.

The single most important nuance: tirzepatide (Mounjaro / Zepbound) is classified by its FDA label as a dual GIP/GLP-1 receptor agonist — not a pure GLP-1. Patients and many clinicians colloquially group tirzepatide with GLP-1s; the label disagrees. We follow the label.

What this article is not: medical advice. Indication, dose, and brand selection are clinical decisions made between a patient and their prescriber.

The two simplest rules

Most disambiguation questions resolve to one of two rules:

  1. Same molecule → different brand for different indication. Wegovy and Ozempic are both semaglutide; Zepbound and Mounjaro are both tirzepatide; Saxenda and Victoza are both liraglutide. The brand split exists because the FDA approves drugs by indication, and a higher-dose obesity-indicated brand needs a separate regulatory filing from the diabetes-indicated brand.
  2. Different molecule → different drug entirely. Wegovy (semaglutide) is not Mounjaro (tirzepatide). Ozempic (semaglutide) is not Trulicity (dulaglutide). Foundayo (orforglipron) is not Rybelsus (oral semaglutide). Different molecules have different efficacy, different side-effect profiles, different dosing schedules, and different manufacturers.

Almost every is X the same as Y question can be answered by identifying which active ingredient is in each brand and applying these two rules.

Wegovy vs Ozempic vs Saxenda (semaglutide and liraglutide brand families)

Three Novo Nordisk brand families dominate this confusion:

  • Semaglutide injectables: Wegovy (2.4 mg once weekly, FDA-approved for chronic weight management) and Ozempic (up to 2.0 mg once weekly, FDA-approved for type 2 diabetes). Same molecule, different brands, different maximum doses, different indications [1, 2].
  • Semaglutide oral: Rybelsus (3, 7, or 14 mg once daily, FDA-approved for type 2 diabetes only) and, since June 30, 2026, a Wegovy oral tablet (25 mg once daily, same chronic weight-management indication as the Wegovy injection) — both use the SNAC absorption enhancer; Wegovy is no longer injection-only [1, 6].
  • Liraglutide injectables: Saxenda (3 mg/day, FDA-approved for chronic weight management) and Victoza (up to 1.8 mg/day, FDA-approved for type 2 diabetes). Same molecule, different brands, different maximum doses, different indications [3]. Generic liraglutide exists for both indications as of 2024-2025.

For the full comparison table — efficacy, dosing, mechanism, and channel — see the dedicated brand-name cheat sheet .

Mounjaro vs Zepbound (the tirzepatide brand family)

Eli Lilly markets tirzepatide under two brand names:

  • Mounjaro — FDA-approved May 2022 for type 2 diabetes. Maximum dose 15 mg once weekly [5].
  • Zepbound — FDA-approved November 2023 for chronic weight management; expanded December 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity. Maximum dose 15 mg once weekly [4].

The active ingredient, dose strengths, titration schedule, injection device, and safety profile are identical between the two brands. The clinical experience for a patient is the same — only the indication, the package, and (often) the insurance coverage rules differ.

For the full comparison, see Mounjaro vs Zepbound: complete comparison .

Why these brands have multiple versions

The pattern of same molecule, different brand for different indication is older than GLP-1s. Bupropion is sold as Wellbutrin (depression) and Zyban (smoking cessation). Finasteride is sold as Proscar (BPH, 5 mg) and Propecia (male- pattern baldness, 1 mg). Sildenafil is sold as Viagra (ED) and Revatio (pulmonary arterial hypertension).

The pattern reflects three things. First, the FDA reviews and approves drugs by indication, so a manufacturer seeking a new indication for an existing molecule files a separate application with separate trials. Second, dose differences between indications often justify a separate package and label (Saxenda 3 mg/day vs Victoza 1.8 mg/day, Wegovy 2.4 mg vs Ozempic 2.0 mg). Third, payer coverage and prescribing patterns differ across indications, and a separate brand makes it easier for prescribers, pharmacists, and payers to track utilization to the correct indication.

Drug-class confusion: GLP-1 vs Ozempic

GLP-1 is the name of a drug class. It is short for “glucagon-like peptide-1 receptor agonist” — a category of medications that bind to and activate the GLP-1 receptor. Many drugs are in this class, including:

  • Semaglutide (Wegovy, Ozempic, Rybelsus — Novo Nordisk)
  • Liraglutide (Saxenda, Victoza, Hikma generic, Teva generic)
  • Dulaglutide (Trulicity — Eli Lilly, Fc-fusion biologic)
  • Exenatide (Byetta and Bydureon BCise — discontinued by AstraZeneca October 2024; Amneal generic exenatide approved November 2024)
  • Orforglipron (Foundayo — Eli Lilly, oral non-peptide)

Ozempic is one specific drug (semaglutide injection for type 2 diabetes) within this class. Saying “I'm on a GLP-1” tells you the class but not the specific drug. Saying “I'm on Ozempic” tells you the specific drug — and identifies the molecule (semaglutide), manufacturer (Novo Nordisk), indication (type 2 diabetes), and dose range (up to 2.0 mg once weekly).

Tirzepatide is a dual agonist, not a GLP-1 alone

This is the single most important clinical nuance in the article. Tirzepatide — the active ingredient in Mounjaro and Zepbound — is described in §12.1 of the FDA-approved DailyMed labels as “a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist” [4, 5]. It activates both the GIP and GLP-1 receptors.

That distinction matters because:

  • The mechanism is genuinely different. GIP activation contributes additively to weight loss and glycemic control on top of GLP-1 activation, which is one reason tirzepatide produces greater weight loss than semaglutide head-to-head (SURMOUNT-5, NEJM 2025).
  • Class-effect language can mislead. A claim like “all GLP-1s cause X side effect” may apply differently to tirzepatide because of the GIP contribution. Side-effect rates from tirzepatide trials should not be directly extrapolated from semaglutide trials and vice versa.
  • Some emerging investigational drugs add a third receptor. Retatrutide (Eli Lilly investigational) is a triple agonist of GIP, GLP-1, and glucagon receptors — a different class again. The pipeline is increasingly multi-receptor.

In casual conversation, grouping tirzepatide with the GLP-1s is acceptable shorthand. In a clinical context — drug comparisons, side-effect attribution, mechanism explanations — the dual-agonist classification is the correct one and the FDA label uses it explicitly.

All 21 questions answered

1. Is Wegovy the same as Ozempic?

YES — same active ingredient, different brand. Wegovy and Ozempic both contain semaglutide and are both made by Novo Nordisk. They differ in:

  • FDA-approved indication: Wegovy for chronic weight management; Ozempic for type 2 diabetes.
  • Maximum dose: Wegovy 2.4 mg once weekly; Ozempic up to 2.0 mg once weekly.
  • Pen format: Wegovy single-dose pre-filled pens; Ozempic multi-dose pens [1, 2].

2. Is Zepbound the same as Mounjaro?

YES — same active ingredient, different brand. Both contain tirzepatide and are made by Eli Lilly. They share the same dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg), the same once-weekly schedule, and the same titration. They differ in indication: Zepbound for chronic weight management plus obstructive sleep apnea in adults with obesity; Mounjaro for type 2 diabetes [4, 5].

3. Is Saxenda the same as Victoza?

YES — same active ingredient, different brand and dose. Both contain liraglutide and are made by Novo Nordisk. Saxenda titrates to 3 mg/day for chronic weight management; Victoza titrates to a maximum of 1.8 mg/day for type 2 diabetes [3]. Generic liraglutide is now FDA-approved for both indications (Hikma 2024 referencing Victoza, Teva 2025 referencing Saxenda).

4. Is Rybelsus the same as Ozempic?

Same active ingredient, different formulation. Both contain semaglutide and are made by Novo Nordisk. Rybelsus is an oral tablet using the SNAC absorption enhancer to allow gastrointestinal absorption of the peptide. Ozempic is a subcutaneous injection. Both are FDA-approved for type 2 diabetes only — neither is approved for chronic weight management [2, 6].

5. Is Mounjaro a semaglutide?

NO. Mounjaro is tirzepatide, made by Eli Lilly. Tirzepatide is a dual GIP/GLP-1 receptor agonist, chemically and mechanistically different from semaglutide [5]. Patients sometimes confuse the two because both are once-weekly injectable peptides FDA-approved for type 2 diabetes — but they are different drugs from different manufacturers.

6. Is Zepbound a semaglutide?

NO. Zepbound is tirzepatide, made by Eli Lilly — the same molecule as Mounjaro. Wegovy is the semaglutide-based product approved for chronic weight management; Zepbound is the tirzepatide-based product approved for chronic weight management. They are different molecules with different mechanisms [1, 4].

7. Is Wegovy a tirzepatide?

NO. Wegovy is semaglutide 2.4 mg, made by Novo Nordisk. It is a pure GLP-1 receptor agonist [1]. Tirzepatide is the active ingredient in Mounjaro and Zepbound from Eli Lilly. Patients searching for “tirzepatide Wegovy” or “Wegovy tirzepatide” are conflating two different brands from two different manufacturers.

8. Is Foundayo the same as Rybelsus?

NO. Foundayo is orforglipron, a non-peptide small-molecule GLP-1 receptor agonist made by Eli Lilly, FDA-approved on April 1, 2026 for chronic weight management. Rybelsus is oral semaglutide — a peptide formulated with the SNAC absorption enhancer — made by Novo Nordisk and approved for type 2 diabetes only [6]. Different molecules, different chemistry classes (small-molecule vs peptide), different indications, different food restrictions, different manufacturers.

9. Is Trulicity the same as Ozempic?

NO. Trulicity contains dulaglutide — a long-acting GLP-1 receptor agonist Fc-fusion biologic consisting of two GLP-1 analog peptides covalently linked to an Fc fragment of human IgG4 [7]. Ozempic contains semaglutide, a synthetic peptide [2]. Both are once-weekly subcutaneous injections approved for type 2 diabetes only, but they are structurally and chemically different molecules from different manufacturers (Eli Lilly vs Novo Nordisk).

10. Is Wegovy a GLP-1?

YES. Wegovy contains semaglutide, a GLP-1 receptor agonist. The Wegovy DailyMed §12.1 mechanism of action describes semaglutide as a glucagon-like peptide-1 (GLP-1) analog [1]. It is one of the prototypical drugs in the GLP-1 class.

11. Is Mounjaro a GLP-1?

Partially. Tirzepatide — the active ingredient in Mounjaro and Zepbound — is described in §12.1 of both DailyMed labels as “a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist” [4, 5]. It activates both receptors. In casual conversation it is often grouped with the GLP-1s; in clinical and FDA-label terms it is a dual incretin agonist — a related but distinct class.

This nuance matters when extrapolating side-effect rates, head-to-head efficacy, or mechanism-based reasoning. See the section above on “Tirzepatide is a dual agonist” for why this is the most important distinction in the article.

12. Is Foundayo a GLP-1?

YES. Foundayo contains orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. Unlike peptide GLP-1s (semaglutide, liraglutide), orforglipron is a small molecule that binds the GLP-1 receptor through an allosteric site. The mechanism class — GLP-1 receptor agonism — is the same; the chemistry (small-molecule vs peptide) is different.

13. Is Trulicity a GLP-1?

YES. Trulicity contains dulaglutide, a long-acting GLP-1 receptor agonist consisting of two GLP-1 analog peptides covalently linked to an Fc fragment of human IgG4 [7]. It is a biologic GLP-1 receptor agonist, and the DailyMed §12.1 mechanism of action describes it as such.

14. Is GLP-1 the same as Ozempic?

NO. GLP-1 is a drug class — the category of medications that activate the glucagon-like peptide-1 receptor. Ozempic is one specific drug (semaglutide injection for type 2 diabetes) within that class. Saying “GLP-1” in conversation does not specify which drug; saying “Ozempic” identifies a single molecule, brand, manufacturer, indication, and dose range.

15. Is semaglutide a GLP-1?

YES. Semaglutide is a synthetic peptide GLP-1 receptor agonist. It is the active ingredient in Wegovy (weight management — available as an injection and, since June 30, 2026, a 25 mg oral tablet), Ozempic (type 2 diabetes injectable), and Rybelsus (type 2 diabetes oral tablet) — all made by Novo Nordisk [1, 2, 6].

16. Is GLP-1 the same as semaglutide?

NO. GLP-1 is the broader drug class. Semaglutide is one specific molecule within that class. Liraglutide, dulaglutide, exenatide, orforglipron, and (with the dual-mechanism caveat) tirzepatide are also in or adjacent to the GLP-1 class. Saying “GLP-1” can refer to any of them; saying “semaglutide” refers to a single molecule.

17. Is Wegovy the same as Saxenda?

NO. Both are FDA-approved for chronic weight management and both are made by Novo Nordisk, but the active ingredients differ. Wegovy is semaglutide 2.4 mg once weekly; Saxenda is liraglutide 3 mg once daily. Semaglutide is the longer-acting and more potent of the two — STEP-1 reported ~14.9% weight loss at 68 weeks vs ~5-6% historically for liraglutide 3 mg over 56 weeks.

18. Is Wegovy the same as Mounjaro?

NO. Wegovy is semaglutide 2.4 mg (Novo Nordisk), FDA-approved for chronic weight management. Mounjaro is tirzepatide up to 15 mg (Eli Lilly), FDA-approved for type 2 diabetes only. Different molecules (GLP-1 only vs dual GIP/GLP-1), different mechanisms, different manufacturers, different indications [1, 5].

For the side-by-side decision guide, see Wegovy vs Mounjaro: different molecules, different indications .

19. Is Zepbound the same as Wegovy?

NO. Both are FDA-approved for chronic weight management — but they are different molecules. Zepbound is tirzepatide (Eli Lilly, dual GIP/GLP-1 receptor agonist). Wegovy is semaglutide (Novo Nordisk, GLP-1 receptor agonist). SURMOUNT-5 (NEJM 2025) compared the two head-to-head in chronic weight management; tirzepatide produced greater mean weight loss [1, 4].

20. Is generic semaglutide the same as Ozempic or Wegovy?

No FDA-approved generic semaglutide is on the market in the United States as of August 2026. Ozempic, Wegovy, and Rybelsus remain branded products under Novo Nordisk's active patent. Apotex Inc. holds a tentative FDA approval (ANDA 220314, dated April 2026) for generic injectable semaglutide — tentative approval confirms the generic met FDA's quality/bioequivalence bar but does not permit marketing until Novo Nordisk's patent/exclusivity protection lapses. Patients sometimes refer to compounded semaglutide as a “generic” — this is incorrect. Compounded semaglutide produced by 503A and 503B compounding pharmacies is not an FDA-approved generic; it is a pharmacy- compounded preparation, regulated differently under FDCA §503A and §503B. The FDA has explicitly stated that compounded semaglutide does not have the FDA-approved generic designation.

21. Is generic liraglutide the same as Saxenda or Victoza?

YES — FDA-approved generic liraglutide exists. Hikma received FDA approval in December 2024 for the first generic liraglutide referencing Victoza (type 2 diabetes indication) — the first FDA-approved generic GLP-1 receptor agonist of any kind. Teva received FDA approval on August 28, 2025 for the first generic liraglutide 3 mg referencing Saxenda (chronic weight management indication) — the first FDA-approved generic GLP-1 receptor agonist for chronic weight management. As FDA-approved generics, both products are bioequivalent to their reference brands.

Quick-reference disambiguation table

BrandActive ingredientManufacturerFDA indicationBrand-family siblings
WegovySemaglutide 2.4 mgNovo NordiskChronic weight managementOzempic, Rybelsus (same molecule)
OzempicSemaglutide up to 2.0 mgNovo NordiskType 2 diabetesWegovy, Rybelsus (same molecule)
RybelsusSemaglutide oral (3 / 7 / 14 mg)Novo NordiskType 2 diabetesWegovy, Ozempic (same molecule, different formulation)
SaxendaLiraglutide 3 mg/dayNovo NordiskChronic weight managementVictoza (same molecule); Teva generic available
VictozaLiraglutide up to 1.8 mg/dayNovo NordiskType 2 diabetesSaxenda (same molecule); Hikma generic available
ZepboundTirzepatide up to 15 mgEli LillyChronic weight management + OSA in obesityMounjaro (same molecule)
MounjaroTirzepatide up to 15 mgEli LillyType 2 diabetesZepbound (same molecule)
TrulicityDulaglutide (Fc-fusion biologic)Eli LillyType 2 diabetesNone — single-brand GLP-1
FoundayoOrforglipron (oral non-peptide)Eli LillyChronic weight managementNone — single-brand GLP-1

Magnitude comparison: 4 brands, 2 molecules

The brand split is regulatory; the molecules underneath drive the weight-loss numbers. Wegovy and Ozempic share semaglutide but at different maximum doses — 2.4 mg/wk vs up to 2.0 mg/wk — and across different trial populations (obesity without diabetes for Wegovy; type 2 diabetes for Ozempic). Zepbound and Mounjaro share tirzepatide at the same maximum dose (15 mg/wk), with the gap between trial results explained primarily by population (obesity vs T2D).

Magnitude comparison

Total body-weight reduction at trial endpoint — same molecule, different brand and trial population. Wegovy and Ozempic both contain semaglutide; Zepbound and Mounjaro both contain tirzepatide. Sources: STEP-1 (semaglutide 2.4 mg, obesity), SUSTAIN-7 (semaglutide 1.0 mg, T2D), SURMOUNT-1 (tirzepatide 15 mg, obesity), SURPASS-2 (tirzepatide 15 mg, T2D).[8][9][10][11]

  • Wegovy — semaglutide 2.4 mg (STEP-1, obesity, 68 wk)14.9 % TBWL
    molecule: semaglutide
  • Ozempic — semaglutide 1.0 mg (SUSTAIN-7, T2D, 40 wk)6.5 % TBWL
    molecule: semaglutide (lower dose, T2D population)
  • Zepbound — tirzepatide 15 mg (SURMOUNT-1, obesity, 72 wk)20.9 % TBWL
    molecule: tirzepatide
  • Mounjaro — tirzepatide 15 mg (SURPASS-2, T2D, 40 wk)12 % TBWL
    molecule: tirzepatide (same dose, T2D population)
Total body-weight reduction at trial endpoint — same molecule, different brand and trial population. Wegovy and Ozempic both contain semaglutide; Zepbound and Mounjaro both contain tirzepatide. Sources: STEP-1 (semaglutide 2.4 mg, obesity), SUSTAIN-7 (semaglutide 1.0 mg, T2D), SURMOUNT-1 (tirzepatide 15 mg, obesity), SURPASS-2 (tirzepatide 15 mg, T2D).

Two patterns stand out. First, the same molecule at the same dose produces different weight-loss magnitudes depending on whether the trial enrolled obesity-without-diabetes patients (Wegovy and Zepbound trials) or type-2-diabetes patients (Ozempic and Mounjaro trials). T2D populations consistently lose less weight on the same drug, a pattern documented across the STEP, SUSTAIN, SURMOUNT, and SURPASS programs. Second, the tirzepatide molecule (Zepbound / Mounjaro) outperforms semaglutide (Wegovy / Ozempic) head-to-head in both populations — the magnitude difference attributed to the additional GIP receptor activation.

Bottom line

  • GLP-1 is a drug class. Ozempic is one specific drug in that class. The two are not interchangeable terms.
  • Wegovy and Ozempic are the same active ingredient (semaglutide, Novo Nordisk) at different maximum doses for different FDA-approved indications [1, 2].
  • Zepbound and Mounjaro are the same active ingredient (tirzepatide, Eli Lilly) at the same maximum dose for different FDA-approved indications [4, 5].
  • Saxenda and Victoza are the same active ingredient (liraglutide, Novo Nordisk) at different maximum doses for different FDA-approved indications [3]. Generic liraglutide is now FDA-approved for both indications.
  • Tirzepatide is a dual GIP/GLP-1 receptor agonist — per the verbatim §12.1 of the Mounjaro and Zepbound DailyMed labels — not a pure GLP-1 [4, 5]. This is the single most important nuance in the article.
  • No FDA-approved generic semaglutide is on the market in the United States as of August 2026 (Apotex holds a tentative — not final — ANDA approval, blocked by Novo Nordisk's patent/exclusivity). Compounded semaglutide is not an FDA-approved generic.
  • FDA-approved generic liraglutide exists for both type 2 diabetes (Hikma, Dec 2024) and chronic weight management (Teva, Aug 2025).

Important disclaimer

This article is educational and reports verified brand-to-active-ingredient and brand-to-indication mappings from the FDA-approved DailyMed prescribing information for each product. None of this constitutes medical advice. Indication, dose, brand selection, and switching decisions are clinical decisions made between a patient and their prescriber. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations.

For the side-by-side comparison of all four headline brands, see the Wegovy vs Ozempic vs Zepbound vs Mounjaro brand-name cheat sheet . For the indication-vs-formulation framing in more depth, see diabetes vs weight-loss GLP-1 disambiguation . For the same-molecule, different-brand comparison of the tirzepatide family, see Mounjaro vs Zepbound: complete comparison . For the cross-molecule decision between the two leading chronic-weight-management options, see Wegovy vs Mounjaro: different molecules, different indications . For the full reference list of every FDA-approved GLP-1, see the GLP-1 medication list 2026 . For the oral GLP-1 family (Rybelsus, Foundayo), see GLP-1 pills 2026: Rybelsus vs Foundayo vs oral semaglutide . For the broader GLP-1 overview, see the GLP-1 complete guide .

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablet — US Prescribing Information (DailyMed), SPL version 19 (published Jun 30, 2026), the version that added the 25 mg oral tablet alongside the existing subcutaneous injection. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information (DailyMed). FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  3. 3.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information (DailyMed). FDA Approved Labeling — DailyMed (NIH). 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39c1108c-72c6-4a35-bf68-ad4c07e3146e
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information (DailyMed). Mechanism of action (§12.1): tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32f50f2a-c33c-486a-9ff6-49fee1d6605f
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information (DailyMed). Mechanism of action (§12.1): tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  6. 6.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets — US Prescribing Information (DailyMed). FDA Approved Labeling — DailyMed (NIH). 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39bf1cb7-2334-46b6-a4f6-0c41a8ac2bef
  7. 7.Eli Lilly and Company. TRULICITY (dulaglutide) injection — US Prescribing Information (DailyMed). Long-acting GLP-1 receptor agonist consisting of two GLP-1 analog peptides covalently linked to an Fc fragment of human IgG4. FDA Approved Labeling — DailyMed (NIH). 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050a5-1377-4c0e-b14a-67d9b14c6b1f
  8. 8.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg weekly produced −14.9% body weight at 68 weeks. N Engl J Med. 2021. PMID: 33567185.
  9. 9.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Tirzepatide 15 mg weekly produced −20.9% body weight at 72 weeks. N Engl J Med. 2022. PMID: 35658024.
  10. 10.Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, et al.; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Semaglutide 1.0 mg weekly produced ~6.5% body-weight reduction at 40 weeks. Lancet Diabetes Endocrinol. 2018. PMID: 29397376.
  11. 11.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Tirzepatide 15 mg weekly produced ~12% body-weight reduction at 40 weeks. N Engl J Med. 2021. PMID: 34170647.

Related research

Diabetes Weight Loss Drug — Which Is Which? Untangling Ozempic, Mounjaro, Wegovy, Zepbound, Foundayo (2026)

Confused by all the GLP-1 brand names? Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy, Zepbound, Foundayo, and Saxenda are FDA-approved for chronic weight management. Some share active ingredients with different brand names. This is the short, plain-English untangling — which drug is for diabetes, which is for weight loss, and what insurance will and will not cover.

7 min read

GLP-1 Side Effect Q&A: Headache, Sulfur Burps, Brain Fog, Mood, Acne, and 12 Other Patient Questions

Specific patient-reported GLP-1 side effects with verified rates from STEP-1, SURMOUNT-1, and the FDA prescribing information adverse reactions tables. Includes the headache rate (14.2% sema vs 10% placebo), the sulfur-burp mechanism, the FDA suicidal ideation review conclusion, and the emerging brain fog FDA pharmacovigilance signal.

12 min read

GLP-1 Medication List 2026: Every FDA-Approved & Investigational GLP-1 Drug in One Reference

The complete 2026 reference list of every FDA-approved GLP-1 receptor agonist (Wegovy, Zepbound, Foundayo, Saxenda, Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza, Byetta status, Bydureon BCise status, Hikma generic liraglutide, Teva generic liraglutide, Amneal generic exenatide) plus the major investigational pipeline drugs (retatrutide, MariTide, CagriSema, survodutide, mazdutide, ecnoglutide, pemvidutide, petrelintide). For each: brand name + generic + manufacturer + indication + route + frequency + FDA approval date.

14 min read

GLP-1 Pills (2026): Rybelsus, Foundayo & the New Wegovy Tablet — Side-by-Side Comparison of Every Oral GLP-1

Three FDA-approved oral GLP-1 medications as of a 2026 label update: Rybelsus (semaglutide PO since 2019, T2D-only), Foundayo (orforglipron PO since April 2026, weight management), and Wegovy tablets (high-dose oral semaglutide, added to the Wegovy label in 2026 for cardiovascular risk reduction or weight reduction in adults, based on OASIS-4). All three are once-daily — but the dosing strictness, food restrictions, indications, formulations, and effect sizes differ materially.

13 min read

Ozempic Burps: Why Semaglutide Causes Sulfur Burps & How to Stop Them (2026)

“Ozempic burps” — frequent belching and rotten-egg sulfur burps — are a real, label-consistent effect of semaglutide. Why delayed gastric emptying causes them, the foods that trigger them, prescriber-directed ways to stop them, and the warning signs that need urgent care.

8 min read

Rybelsus Alternatives: When Oral Semaglutide Isn't Working — Switching to Foundayo, Wegovy, or Compounded (2026)

Rybelsus (oral semaglutide, Novo Nordisk) is FDA-approved for type 2 diabetes ONLY — never for weight management — and carries the strictest food-restriction rule in the entire GLP-1 class: take at least 30 minutes before the first food, beverage, or other oral medications, with no more than 4 ounces of plain water (DailyMed §2 verbatim). When Rybelsus isn't working — slow titration to top dose, fasted-morning regimen failure, T2D-only insurance coverage, or modest weight effect from a T2D-trial drug — the FDA-approved oral GLP-1 alternative for chronic weight management is Foundayo (orforglipron, Eli Lilly, FDA-approved April 2026). Injectable alternatives are Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 15 mg) for higher-effect-size weight loss. Compounded oral semaglutide is regulatory gray-zone post-Oct 2024 FDA enforcement-discretion expiration and is NOT a clean alternative.

13 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.8

Care Bare Rx

LGBTQ+-inclusive compounded GLP-1 telehealth

From $199/mo

Get started →
Read full review →
8.2

Enhance MD

Lab-monitored compounded GLP-1 with mandatory video visit

From $169/mo

Get started →
Read full review →
7.3

Liv Body

Compounded GLP-1 paired with a muscle-preservation supplement stack

From $149/mo

Get started →
Read full review →
Compare all 564 vetted providers →Browse the full directoryTop tirzepatide providers →Tirzepatide guide →